Gene clues could personalize breast cancer therapy
NCT ID NCT02329639
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This study looked at how two specific genes (VEGFR-2 and IL-8) might influence how well metastatic breast cancer patients respond to a combination of chemotherapy (paclitaxel) and a targeted drug (bevacizumab) versus chemotherapy alone. Researchers enrolled 307 patients from Italy and tracked how long their cancer stayed under control and overall survival. The goal was to see if genetic differences could help predict which treatment works best for each person.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda USL 5 of Pisa
Pontedera, Pisa, 56025, Italy
-
Department of Clinical and Experimental Medicine, University of Pisa
Pisa, I Am Not in the U.S. Or Canada, 56125, Italy
Conditions
Explore the condition pages connected to this study.